. Even small increments in blood pressure are associated with an increased risk of cardiovascular events 3 . This genome-wide association study of systolic and diastolic blood pressure, which used a multi-stage design in 200,000 individuals of European descent, identified sixteen novel loci: six of these loci contain genes previously known or suspected to regulate blood pressure (GUCY1A3-GUCY1B3, NPR3-C5orf23, ADM, FURIN-FES, GOSR2, GNAS-EDN3); the other ten provide new clues to blood pressure physiology. A genetic risk score based on 29 genomewide significant variants was associated with hypertension, left ventricular wall thickness, stroke and coronary artery disease, but not kidney disease or kidney function. We also observed associations with blood pressure in East Asian, South Asian and African ancestry individuals. Our findings provide new insights into the genetics and biology of blood pressure, and suggest potential novel therapeutic pathways for cardiovascular disease prevention.
Genetic approaches have advanced the understanding of biological pathways underlying inter-individual variation in blood pressure. For example, studies of rare Mendelian blood pressure disorders have identified multiple defects in renal sodium handling pathways 4 . More recently two genome-wide association studies (GWAS), each of .25,000 individuals of European ancestry, identified 13 loci associated with systolic blood pressure (SBP), diastolic blood pressure (DBP) and hypertension 5, 6 . We now report results of a new metaanalysis of GWAS data that includes staged follow-up genotyping to identify additional blood pressure loci.
Primary analyses evaluated associations between 2.5 million genotyped or imputed single nucleotide polymorphisms (SNPs) and SBP and DBP in 69,395 individuals of European ancestry from 29 studies (Supplementary Materials sections 1-3 and Supplementary Tables 1  and 2 ). Following GWAS meta-analysis, we conducted a three-stage validation experiment that made efficient use of available genotyping resources, to follow up top signals in up to 133,661 additional individuals of European descent (Supplementary Fig. 1 and Supplementary Materials section 4). Twenty-nine independent SNPs at 28 loci were significantly associated with SBP, DBP, or both in the meta-analysis combining discovery and follow-up data ( Fig. 1 , Table 1, Supplementary Figs 2, 3 and Supplementary Tables 3-5 ). All 29 SNPs attained association P , 5 3 10
29
, an order of magnitude beyond the standard genome-wide significance level for a single-stage experiment (Table 1) .
Sixteen of these 29 associations were novel (Table 1) . Two associations were near the FURIN and GOSR2 genes; prior targeted analyses of variants in these genes suggested they may be blood pressure loci 7, 8 . At the CACNB2 locus we validated association for a previously reported 6 SNP, rs4373814, and detected a novel independent association for rs1813353 (pairwise r 2 5 0.015 in HapMap CEU). Of our 13 previously reported associations 5, 6 , only the association at PLCD3
was not supported by the current results (Supplementary Table 4) . Some of the associations are in or near genes involved in pathways known to influence blood pressure (NPR3, GUCY1A3-GUCY1B3, ADM, GNAS-EDN3, NPPA-NPPB and CYP17A1; Supplementary  Fig. 4 ). Twenty-two of the 28 loci did not contain genes that were a priori strong biological candidates.
As expected from prior blood pressure GWAS results, the effects of the novel variants on SBP and DBP were small ( Fig. 1 and Table 1 ). For all variants, the observed directions of effects were concordant for SBP, DBP and hypertension ( Fig. 1 , Table 1 and Supplementary Fig. 3 ). Among the genes at the genome-wide significant loci, only CYP17A1, previously implicated in Mendelian congenital adrenal hyperplasia and hypertension, is known to harbour rare variants that have large effects on blood pressure 9 . We performed several analyses to identify potential causal alleles and mechanisms. First, we looked up the 29 genome-wide significant index SNPs and their close proxies (r 2 . 0.8) among cis-acting expression SNP (eSNP) results from multiple tissues (Supplementary Materials section 5). For 13/29 index SNPs, we found an association between nearby eSNP variants and the expression levels of at least one gene transcript (10 24 . P . 10
251
; Supplementary Table 6 ). In five cases, the index blood pressure SNP and the best eSNP from a genomewide survey were identical, highlighting potential mediators of the SNP-blood pressure associations.
Second, because changes in protein sequence are a priori strong functional candidates, we sought non-synonymous coding SNPs that were in high linkage disequilibrium (r 2 . 0.8) with the 29 index SNPs. We identified such SNPs at eight loci (Table 1, Supplementary  Materials section 6 and Supplementary Table 7 ). In addition we performed analyses testing for differences in genetic effect according to body mass index (BMI) or sex, and analyses of copy number variants, pathway enrichment and metabolomic data, but we did not find any statistically significant results (Supplementary Materials sections 7-9  and Supplementary Tables 8-10 ).
We evaluated whether the blood pressure variants we identified in individuals of European ancestry were associated with blood pressure in individuals of East Asian (N 5 29,719), South Asian (N 5 23,977) and African (N 5 19,775) ancestries (Table 1 and Supplementary  Tables 11-13 ). We found significant associations in individuals of East Asian ancestry for SNPs at nine loci and in individuals of South Asian ancestry for SNPs at six loci; some have been reported previously (Supplementary Tables 12 and 15 ). The lack of significant association for individual SNPs may reflect small sample sizes, differences in allele frequencies or linkage disequilibrium patterns, imprecise imputation for some ancestries using existing reference samples, or a genuinely different underlying genetic architecture. Because of limited power to detect effects of individual variants in the smaller non-European samples, we created genetic risk scores for SBP and DBP incorporating all 29 blood pressure variants weighted according to effect sizes observed in the European samples. In each non-European ancestry group, risk scores were strongly associated with SBP (P 5 1.1 3 10 240 in East Asian, P 5 2.9 3 10 213 in South Asian, P 5 9.8 3 10 24 in African ancestry individuals) and DBP (P 5 2.9 3 10
248
, P 5 9.5 3 10 215 and P 5 5.3 3 10 25 , respectively; Supplementary Table 13) . We also created a genetic risk score to assess association of the variants in aggregate with hypertension and with clinical measures of hypertensive complications including left ventricular mass, left ventricular wall thickness, incident heart failure, incident and prevalent stroke, prevalent coronary artery disease (CAD), kidney disease and measures of kidney function, using results from other GWAS consortia (Table 2 , Supplementary Materials sections 10, 11 and Supplementary Table 14 ). The risk score was weighted using the average of SBP and DBP effects for the 29 SNPs. In an independent sample of 23,294 women 10 , an increase of one standard deviation in the genetic risk score was associated with a 23% increase in the odds of hypertension (95% confidence interval 19-28%; Table 2 and Supplementary  Table 14) . Among individuals in the top decile of the risk score, the prevalence of hypertension was 29% compared with 16% in the bottom decile (odds ratio 2.09, 95% confidence interval 1.86-2.36). Similar results were observed in an independent hypertension case-control sample ( Table 2 ). In our study, individuals in the top compared to bottom quintiles of genetic risk score differed by 4.6 mm Hg SBP and 3.0 mm Hg DBP, differences that approach population-averaged blood pressure treatment effects for a single antihypertensive agent 11 . Epidemiological data have shown that differences in SBP and DBP of this magnitude, across the population range of blood pressure, are associated with an increase in cardiovascular disease risk 3 . Consistent with this and in line with findings from randomized trials of blood-pressure-lowering medication in hypertensive patients 12, 13 , the genetic risk score was positively associated with left ventricular wall thickness (P 5 6.0 3 10 26 ), occurrence of stroke (P 5 3.3 3 10
25
) and CAD (P 5 8.1 3 10
229
). The same genetic risk score was not, however, significantly associated with chronic kidney disease or measures of kidney function, even though these renal outcomes were available in a similar sample size as for the other outcomes ( Table 2 ). The absence of association with kidney phenotypes could be explained by a weaker causal relationship between blood pressure and kidney phenotypes than with CAD and stroke. This finding is consistent with the mismatch between observational data that show a positive association of blood pressure with kidney disease, and clinical trial data that show inconsistent evidence of a benefit from blood pressure lowering on kidney disease prevention in patients with hypertension 14 . Thus, several lines of evidence converge to indicate that blood pressure elevation may in part be a consequence rather than a cause of subclinical kidney disease.
Our discovery meta-analysis ( Supplementary Fig. 2 ) suggests an excess of modestly significant (10 25 , P , 10
22
) associations probably arising from common blood pressure variants of small effect. By dividing our principal GWAS data set into non-overlapping discovery (N < 56,000) and validation (N < 14,000) subsets, we found robust evidence for the existence of such undetected common variants (Supplementary Fig. 5 and Supplementary Materials section 12). We estimate 15 that there are 116 (95% confidence interval 57-174) independent blood pressure variants with effect sizes similar to those 
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reported here, which collectively can explain ,2.2% of the phenotypic variance for SBP and DBP, compared with 0.9% explained by the 29 associations discovered thus far ( Supplementary Fig. 6 and Supplementary Materials section 13).
Most of the 28 blood pressure loci harbour multiple genes (Supplementary Table 15 and Supplementary Fig. 4) , and although substantial research is required to identify the specific genes and variants responsible for these associations, several loci contain highly plausible biological candidates. The NPPA and NPPB genes at the MTHFR-NPPB locus encode precursors for atrial-and B-type natriuretic peptides (ANP, BNP), and previous work has identified SNPs-modestly correlated with our index SNP at this locus-which are associated with plasma ANP, BNP and blood pressure 16 . We found the index SNP at this locus was associated with opposite effects on blood pressure and on ANP/BNP levels, consistent with a model in which the variants act through increased ANP/BNP production to lower blood pressure 16 ( Supplementary Materials section 14) . Two other loci identified in the current study harbour genes involved in natriuretic peptide and related nitric oxide signalling pathways 17, 18 , both of which act to regulate cyclic guanosine monophosphate. The first locus contains NPR3, which encodes the natriuretic peptide clearance receptor (NPR-C). NPR3 knockout mice exhibit reduced clearance of circulating natriuretic peptides and lower blood pressure 19 . The second locus includes GUCY1A3 and GUCY1B3, encoding the a and b subunits of soluble guanylate cyclase; knockout of either gene in murine models results in hypertension 20 .
Another locus contains ADM-encoding adrenomedullin-which has natriuretic, vasodilatory and blood-pressure-lowering properties 21 . At the GNAS-EDN3 locus, ZNF831 is closest to the index SNP, but GNAS and EDN3 are two nearby compelling biological candidates ( Supplementary Fig. 4 and Supplementary Table 15) .
We identified two loci with plausible connections to blood pressure via genes implicated in renal physiology or kidney disease. At the first locus, SLC4A7 is an electro-neutral sodium bicarbonate co-transporter expressed in the nephron and in vascular smooth muscle 22 . At the second locus, PLCE1 (phospholipase-C-epsilon-1 isoform) is important for normal podocyte development in the glomerulus; sequence variation in PLCE1 has been implicated in familial nephrotic syndromes and end-stage kidney disease 23 . Missense variants in two genes involved in metal ion transport were associated with blood pressure in our study. The first encodes a His/ Asp change at amino acid 63 (H63D) in HFE and is a low-penetrance allele for hereditary hemochromatosis 24 . The second is an Ala/Thr polymorphism located in exon 7 of SLC39A8, which encodes a zinc transporter that also transports cadmium and manganese 25 . The same allele of SLC39A8 associated with blood pressure in our study has recently been associated with high-density lipoprotein cholesterol levels 26 and BMI 27 (Supplementary Table 15 ). We have shown that 29 independent genetic variants influence blood pressure in people of European ancestry. The variants reside in 28 loci, 16 of which were novel, and we confirmed association of several of them in individuals of non-European ancestry. A risk score Tables 5 and 12 ).
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derived from the 29 variants was significantly associated with bloodpressure-related organ damage and clinical cardiovascular disease, but not kidney disease. These loci improve our understanding of the genetic architecture of blood pressure, provide new biological insights into blood pressure control and may identify novel targets for the treatment of hypertension and the prevention of cardiovascular disease. Note added in proof: Since this manuscript was submitted, Kato et al. published a blood pressure GWAS in East Asians that identified a SNP highly correlated to the SNP we report at the NPR3/C5orf23 locus 28 .
METHODS SUMMARY
Supplementary Materials provide complete methods and include the following sections: study recruitment and phenotyping, adjustment for antihypertensive medications, genotyping, data quality control, genotype imputation, withincohort association analyses, meta-analyses of discovery and validation stages, stratified analyses by sex and BMI, identification of eSNPs and non-synonymous SNPs, metabolomic and lipidomic analyses, CNV analyses, pathway analyses, analyses for non-European ancestries, association of a risk score with hypertension and cardiovascular disease, estimation of numbers of undiscovered variants, measurement of natriuretic peptides, and brief literature reviews and GWAS database lookups of all validated blood pressure loci. Full GWAS results for <2.5 million SNPs are also provided. 
